In DLBCL, FAK is highly expressed (Figure 2) and has been revealed to be a valid positive prognostic factor, considering that higher FAK expression (by immunohistochemistry) is associated with longer overall survival and progression-free survival with respect to the cases with a lower FAK expression; therefore, FAK could be a new molecular marker that is useful for refining the risk stratification of DLBCL patients (73). This evidence concerns the gene PTK2 and diffuse large B-cell lymphoma.